Onyinyechi Lydia Ugorji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Onyinyechi Lydia Ugorji has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Amarauche Chukwu
Department of Pharmaceutical Technology and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria
2 shared publications- Chinekwu Sherridan Nwagwu
Drug Delivery and Nanomedicines Research Laboratory, Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria
2 shared publications Ikechukwu Virgilius Onyishi
Department of Pharmaceutical Technology and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria
2 shared publicationsNicholas Chinedu Obitte
Department of Pharmaceutical Technology and Industrial Pharmacy, University of Nigeria, Nsukka, Nigeria
2 shared publications- Adaeze Chidiebere Echezona
Drug Delivery and Nanomedicines Research Laboratory, Department of Pharmaceutics, University of Nigeria, Nsukka 410001, Enugu State, Nigeria
1 shared publication - Adaeze Linda Onugwu
Drug Delivery and Nanomedicines Research Laboratory, Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria
1 shared publication
Latest Publications
- Open Access
- 4 January 2024
- Published by Springer Nature in Beni-Suef University Journal of Basic and Applied Sciences
- Vol. 13 (1) , 1-24
Solubility enhancing lipid-based vehicles for artemether and lumefantrine destined for the possible treatment of induced malaria and inflammation: in vitro and in vivo evaluations
Background: The lipid self-emulsifying system has been advanced as a promising delivery vehicle for improving the solubility and bioavailability of artemether and lumefantrine. However, the observed kinetic instability (propensity of lumefantrine to rapid crystallisation from nano-scale droplets) in aqueous acid has impelled some researchers to incorporate surfactants/solubilizers in the dissolution medium prior to dissolution studies. Thus, in our present work, we sought to prepare micro/large nano-scale (> 100 nm) and yet kinetically stable lumefantrine lipid self-emulsifying system (that would not require an external drug dissolution enhancing agent in the dissolution medium) and palm kernel oil-based 100 nm kinetically stable artemether lipid self-emulsifying system with rapid emulsification time. COVID-19 and Plasmodium falciparum-infected Africans with previous long exposure to malaria have manifested attenuated inflammatory cytokines more than malaria-naive patients. Therefore, the ingestion of artemether-lumefantrine with enhanced solubility may further promote blunting of cytokines. Therefore, this work was aimed at preparing (< 100 nm) stable artemether and aqueous acid-stable micro/large nano-scale (> 100 nm) lumefantrine lipid self-emulsifying system destined for improved antimalarial and anti-inflammatory activities. Results: The droplet sizes of all the liquid artemether and lumefantrine formulations were between 8.95–39.88 and 1018–4195 nm, respectively. The loading efficiency for all the formulations was, between 72.91 ± 2.89 and 100.00 ± 0.29%. All the artemether and lumefantrine batches emulsified within the range of 3.90 ± 0.69 to 12.26 ± 0.69 s. Stable and transparent emulsions were formed on aqueous dilution to 1000 ml. The percentage drug released for artemether and lumefantrine ranged from 76.25 ± 2.98 to 99.22 ± 1.61%. The solid lipid self-emulsifying systems produced, had fair and passable flow properties. Differential scanning calorimetry revealed that the solid artemether and lumefantrine lipid self-emulsifying system were amorphous. Solidification with Neusilin FH2 or surfactant replacement with Kolliphor EL and Kollidon VA 64 fine prevented micro-or large nano-scale lumefantrine lipid self-emulsifying system from crystallisation in aqueous acid (pH 1.2). Higher antimalarial activity and remarkable anti-inflammatory effects (P < 0.05) favoured the lipid self-emulsifying formulations. Conclusion: Optimal in vitro and in vivo results (enhanced antimalarial and anti-inflammatory activities) were obtained with kinetically stable lumefantrine micro/large nano-scale droplets and kinetically stable palm kernel oil-based (< 50 nm) artemether lipid self-emulsifying system droplets.
- 4 January 2024
- Published by Springer Nature in Beni-Suef University Journal of Basic and Applied Sciences
- Vol. 13 (1) , 1-24
Open AccessSolubility enhancing lipid-based vehicles for artemether and lumefantrine destined for the possible treatment of induced malaria and inflammation: in vitro and in vivo evaluations
Background: The lipid self-emulsifying system has been advanced as a promising delivery vehicle for improving the solubility and bioavailability of artemether and lumefantrine. However, the observed kinetic instability (propensity of lumefantrine to rapid crystallisation from nano-scale droplets) in aqueous acid has impelled some researchers to incorporate surfactants/solubilizers in the dissolution medium prior to dissolution studies. Thus, in our present work, we sought to prepare micro/large nano-scale (> 100 nm) and yet kinetically stable lumefantrine lipid self-emulsifying system (that would not require an external drug dissolution enhancing agent in the dissolution medium) and palm kernel oil-based 100 nm kinetically stable artemether lipid self-emulsifying system with rapid emulsification time. COVID-19 and Plasmodium falciparum-infected Africans with previous long exposure to malaria have manifested attenuated inflammatory cytokines more than malaria-naive patients. Therefore, the ingestion of artemether-lumefantrine with enhanced solubility may further promote blunting of cytokines. Therefore, this work was aimed at preparing (< 100 nm) stable artemether and aqueous acid-stable micro/large nano-scale (> 100 nm) lumefantrine lipid self-emulsifying system destined for improved antimalarial and anti-inflammatory activities. Results: The droplet sizes of all the liquid artemether and lumefantrine formulations were between 8.95–39.88 and 1018–4195 nm, respectively. The loading efficiency for all the formulations was, between 72.91 ± 2.89 and 100.00 ± 0.29%. All the artemether and lumefantrine batches emulsified within the range of 3.90 ± 0.69 to 12.26 ± 0.69 s. Stable and transparent emulsions were formed on aqueous dilution to 1000 ml. The percentage drug released for artemether and lumefantrine ranged from 76.25 ± 2.98 to 99.22 ± 1.61%. The solid lipid self-emulsifying systems produced, had fair and passable flow properties. Differential scanning calorimetry revealed that the solid artemether and lumefantrine lipid self-emulsifying system were amorphous. Solidification with Neusilin FH2 or surfactant replacement with Kolliphor EL and Kollidon VA 64 fine prevented micro-or large nano-scale lumefantrine lipid self-emulsifying system from crystallisation in aqueous acid (pH 1.2). Higher antimalarial activity and remarkable anti-inflammatory effects (P < 0.05) favoured the lipid self-emulsifying formulations. Conclusion: Optimal in vitro and in vivo results (enhanced antimalarial and anti-inflammatory activities) were obtained with kinetically stable lumefantrine micro/large nano-scale droplets and kinetically stable palm kernel oil-based (< 50 nm) artemether lipid self-emulsifying system droplets.
- Open Access
Quinine: Redesigned and Rerouted
Quinine hydrochloride (QHCl) has remained a very relevant antimalarial drug 400 years after its effectiveness was discovered. Unlike other antimalarials, the development of resistance to quinine has been slow. Hence, this drug is to date still used for the treatment of severe and cerebral malaria, for malaria treatment in all trimesters of pregnancy, and in combination with doxycycline against multidrug-resistant malaria parasites. The decline in its administration over the years is mainly associated with poor tolerability due to its gastrointestinal (GIT) side effects such as cinchonism, complex dosing regimen and bitter taste, all of which result in poor compliance. Hence, our research was aimed at redesigning quinine using nanotechnology and investigating an alternative route for its administration for the treatment of malaria. QHCl nanosuspension (QHCl-NS) for intranasal administration was prepared using lipid matrices made up of solidified reverse micellar solutions (SRMS) comprising Phospholipon® 90H and lipids (Softisan® 154 or Compritol®) in a 1:2 ratio, while Poloxamer® 188 (P188) and Tween® 80 (T80) were used as a stabilizer and a surfactant, respectively. The QHCl-NS formulated were in the nanosize range (68.60 ± 0.86 to 300.80 ± 10.11 nm), and highly stable during storage, though zeta potential was low (≤6.95 ± 0.416). QHCl-NS achieved above 80% in vitro drug release in 6 h. Ex vivo permeation studies revealed that formulating QHCl as NS resulted in a 5-fold and 56-fold increase in the flux and permeation coefficient, respectively, thereby enhancing permeation through pig nasal mucosa better than plain drug solutions. This implies that the rate of absorption as well as ease of drug permeation through porcine nasal mucosa was impressively enhanced by formulating QHCl as NS. Most importantly, reduction in parasitaemia in mice infected with Plasmodium berghei ANKA by QHCl-NS administered through the intranasal route (51.16%) was comparable to oral administration (52.12%). Therefore, redesigning QHCl as NS for intranasal administration has great potential to serve as a more tolerable option for the treatment of malaria in endemic areas.
Open AccessQuinine: Redesigned and Rerouted
Quinine hydrochloride (QHCl) has remained a very relevant antimalarial drug 400 years after its effectiveness was discovered. Unlike other antimalarials, the development of resistance to quinine has been slow. Hence, this drug is to date still used for the treatment of severe and cerebral malaria, for malaria treatment in all trimesters of pregnancy, and in combination with doxycycline against multidrug-resistant malaria parasites. The decline in its administration over the years is mainly associated with poor tolerability due to its gastrointestinal (GIT) side effects such as cinchonism, complex dosing regimen and bitter taste, all of which result in poor compliance. Hence, our research was aimed at redesigning quinine using nanotechnology and investigating an alternative route for its administration for the treatment of malaria. QHCl nanosuspension (QHCl-NS) for intranasal administration was prepared using lipid matrices made up of solidified reverse micellar solutions (SRMS) comprising Phospholipon® 90H and lipids (Softisan® 154 or Compritol®) in a 1:2 ratio, while Poloxamer® 188 (P188) and Tween® 80 (T80) were used as a stabilizer and a surfactant, respectively. The QHCl-NS formulated were in the nanosize range (68.60 ± 0.86 to 300.80 ± 10.11 nm), and highly stable during storage, though zeta potential was low (≤6.95 ± 0.416). QHCl-NS achieved above 80% in vitro drug release in 6 h. Ex vivo permeation studies revealed that formulating QHCl as NS resulted in a 5-fold and 56-fold increase in the flux and permeation coefficient, respectively, thereby enhancing permeation through pig nasal mucosa better than plain drug solutions. This implies that the rate of absorption as well as ease of drug permeation through porcine nasal mucosa was impressively enhanced by formulating QHCl as NS. Most importantly, reduction in parasitaemia in mice infected with Plasmodium berghei ANKA by QHCl-NS administered through the intranasal route (51.16%) was comparable to oral administration (52.12%). Therefore, redesigning QHCl as NS for intranasal administration has great potential to serve as a more tolerable option for the treatment of malaria in endemic areas.
- 8 March 2023
- Published by Taylor & Francis in Journal of Dispersion Science and Technology
- Vol. 45 (5) , 891-899
Soluplus-stabilized 5-fluorouracil-entrapped niosomal formulations prepared via active and passive loading techniques: comparative physico-chemical evaluation
The objective of this study was to prepare and conduct a comparative analysis on 5-fluorouracil (5FU) niosomes stabilized with or without Soluplus, utilizing, respectively, passive loading and active loading techniques. Cholesterol was combined with Span 40 and Tween 40 surfactants to prepare several niosomal formulations by either passive or active methods. Encapsulation efficiency (EE%), loading capacity (LC), mean particle sizes, polydispersity indices (PDI), scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), pH stability, and in vitro drug release in bio relevant media of pH 1.2, 6.8, and 7.4 were employed to evaluate the formulations. Batches made using the active loading approach (B1-B5) demonstrated higher entrapment efficiency (25–40%) (p ˂ 0.05) than those made using the passive loading method (20%) (with the exception of batch A1). In comparison to niosomes made using the passive loading method, the active loading methodology produced niosomes with a lower PDI (˂ 0.25) and particle size (˂ 70 nm). SEM revealed spherical and discrete vesicles for the Soluplus stabilized niosomes. Both approaches produced niosomes with prominent hydrogen bonding as observed in the FTIR study. The formulations were stable and sustained drug release, but the active loading strategy imparted a more sustained release pattern than the passively loaded one. Soluplus stabilized niosomes demonstrated higher (p ˂ 0.05) drug release (60–70%) in all release media. Based on the production of smaller particle sizes and narrower size distribution, the active loading strategy may be a more effective way to load hydrophilic medicines such as 5FU into niosomes. Graphical Abstract
- 8 March 2023
- Published by Taylor & Francis in Journal of Dispersion Science and Technology
- Vol. 45 (5) , 891-899
Soluplus-stabilized 5-fluorouracil-entrapped niosomal formulations prepared via active and passive loading techniques: comparative physico-chemical evaluation
The objective of this study was to prepare and conduct a comparative analysis on 5-fluorouracil (5FU) niosomes stabilized with or without Soluplus, utilizing, respectively, passive loading and active loading techniques. Cholesterol was combined with Span 40 and Tween 40 surfactants to prepare several niosomal formulations by either passive or active methods. Encapsulation efficiency (EE%), loading capacity (LC), mean particle sizes, polydispersity indices (PDI), scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), pH stability, and in vitro drug release in bio relevant media of pH 1.2, 6.8, and 7.4 were employed to evaluate the formulations. Batches made using the active loading approach (B1-B5) demonstrated higher entrapment efficiency (25–40%) (p ˂ 0.05) than those made using the passive loading method (20%) (with the exception of batch A1). In comparison to niosomes made using the passive loading method, the active loading methodology produced niosomes with a lower PDI (˂ 0.25) and particle size (˂ 70 nm). SEM revealed spherical and discrete vesicles for the Soluplus stabilized niosomes. Both approaches produced niosomes with prominent hydrogen bonding as observed in the FTIR study. The formulations were stable and sustained drug release, but the active loading strategy imparted a more sustained release pattern than the passively loaded one. Soluplus stabilized niosomes demonstrated higher (p ˂ 0.05) drug release (60–70%) in all release media. Based on the production of smaller particle sizes and narrower size distribution, the active loading strategy may be a more effective way to load hydrophilic medicines such as 5FU into niosomes. Graphical Abstract